Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Can Reset Reputation In Pandemic, Says Novartis CEO

'Once-In-A-Generation Opportunity'

Executive Summary

Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

You may also be interested in...



Sanofi/Regeneron Refocus Kevzara COVID-19 Trial On Critical Patients, Showing Value Of A Proper Trial

A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.

US FDA Safety Alert For Hydroxychloroquine Is Latest Turn In Drug's Strange Journey

As potentially life-threatening heart problems emerge in coronavirus patients, FDA says hydroxychloroquine should be taken only in clinical trial or hospital settings under the Emergency Use Authorization.

Novartis CEO Backs Malaria Drug Against COVID-19

A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel